Novo Nordisk Expects FDA Feedback on Liraglutide Within Days

Shares

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide is expected within weeks.
Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high, and by inhibiting appetite.
In Europe, Novo Nordisk received marketing authorization for liraglutide under the brand name Victoza® on 30 June 2009.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
0
Would love your thoughts, please comment.x
()
x